Post-earnings recap
Reported
Thu, Aug 6, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 5.81%. The company did not provide revenue figures or future guidance, but management's comments suggest a focus on ongoing projects. Investors may view the EPS surprise as a sign of potential stability in the company's financials.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.87 | N/A | +28.10% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.